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We present the case of a 48-year old male patient with chronic
motor complete SCI, who beneﬁted from a 5-day period of bilateral
L2-level DRG-stimulation by experiencing suppression of transfer-
evoked spasticity problems and of chronic lower back pain. To
the best of our knowledge, this is the ﬁrst case describing the suc-
cessful application of DRG-stimulation for spasticity depression in
patients with chronic SCI.
Clinical presentation
A 48 year-old male patient with a 25-year history of a Th8motor
complete (AIS B) Spinal Cord Injury (SCI) after a bullet injury was
enrolled in our clinical case series (MEC2017-037) in the Erasmus
Medical Center, Rotterdam, The Netherlands. The primary aim of
the study was to evoke motor responses in the corresponding mus-
cles (i.e. m. quadriceps femoris) using DRG-stimulation. Extensive
medical anamnesis and neurological examination by a Physical
and Rehabilitation Medicine physician (RO), revealed a history of
stable, transfer-evoked spasticity, commencing directly after the
trauma. Triggers for spasticity attacks included moving in the
wheelchair after longer durations of sitting (e.g., behind the com-
puter), riding over obstacles and moving from sitting to supine po-
sition. These spastic attacks in supine position always involved
involuntary ﬂexion of the right hip with extension of the right
knee, accompanied by ﬂexion in the left hip and knee, lasting
10e15 seconds. The patient rated the average perceived severity
of spasticity as ‘8’ on the Numeric Rating Scale (NRS, ranging
from ‘0’ (no spasticity) to ‘10’ (worst spasticity imaginable)). Addi-
tionally, he scored his spasms on the self-reported Penn Spasm Fre-
quency Scale (PSFS) [1], with a score of ‘2’ (infrequent full spasms
occurring less than once per hour) in the spasm frequency domain
and a score of ‘3’ (Severe) in the domain of spasm severity. The pa-
tient reported a history of unsuccessful symptomatic treatment
with oral baclofen use (20 mg, 3/day), which was stopped 8 years
prior to inclusion. Concerning other medication, he used Imatinib
(400 mg, 1/day) for his history of chronic myeloid leukemiaAssociation Impairment
, Penn Spasm Frequency
or Spasticity; SCI, Spinal
Inc. This is an open access article uhich was diagnosed 7 years prior to inclusion and oxybu-
tynin (5 mg, 3/day) for bladder hyperreﬂexia. Additionally, the pa-
tient complained of chronic pain problems bilaterally in the lower
back, described as burning and stinging sensations, worsening dur-
ing spastic attacks, accompanied by non-painful, but continuous
paresthesias in the feet. The patient reported an ‘8’ on the NRS
for pain perception.
The patient received conventional DRG-leads (Abbott, Plano,
Texas) as used for chronic pain treatment on spinal level L2 bilater-
ally using a minimally invasive surgical technique under local anes-
thesia, as described earlier by our group (Fig. 1A and B) [2]. Leads
were left externalized and connected to a pulse generator (Pro-
claim™ DRG). Leads were left in situ over a period of 5 days
(Fig. 1C), during which the patient was continuously bilaterally
stimulated with a motor-subthreshold protocol (0,1 mA, 4 Hz,
1000 ms) at home. The patient was asked to keep a patient diary
during DRG-stimulation (day 1e5), as well as after the stimulation
period (day 6e13); the diary included questions concerning 1) po-
tential changes in severity and/or frequency of spasticity (PSFS,
NRS), 2) potential (changes in) pain sensations (NRS), and 3) signs
of other side-effects. Additionally, we assessed the clinical status
using the Modiﬁed Ashworth Scale (MAS), the Spinal Cord Assess-
ment Tool for Spasticity (SCATS), and general measurements of re-
ﬂexes [3] during, as well as directly (on day 5) and 1-week (day 13)
after stimulation.
From day 2 up to day 6 (one day post-stimulation), the patient
reported a reduced severity and frequency of his spasticity (PSFS,
NRS) and lower back pain (NRS), both of which disappeared
completely in the post-stimulation period (Fig. 1D). However, on
day 13 the patient reported return of spasticity with a severity
and frequency close to baseline. Clinical measurements on day 5
and 13 revealed less obvious improvements, with only the SCATS
showing a slight reduction in extensor spasm post-stimulation
(supplement 1).Discussion
Spasticity is a complicated and heterogenous complex of symp-
toms, which can severely affect patients with upper motor neuron
disease. Close to 70% of all patients with chronic SCI are affected by
these involuntary muscle activations [4] which are thought to
result from the interplay between hyperexcitability of interneurons
in the spinal cord and decrease of post-synaptic inhibition [5].
Currently available clinical treatments such as surgical interven-
tions and intrathecal drug administration leave room fornder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Overview of the case report as presented in this paper. A) The patient was implanted with conventional DRG-leads (1) as used for chronic pain treatment, connected to a
pulse generator (2), which could be controlled with a clinician’s programmer (3). B) Intra-operative X-ray images from a lateral (Left) and frontal (Right) view, showing the bilateral
placement of the DRG-leads on the L2-level. C) Overview of the study design, with 2 EMG-measurements (day 1 and day 5), and a subthreshold stimulation period in between (0,1
mA, 4 Hz, 1000 ms). Between day 6e13, the patient was followed-up. The grey line indicates the continuous self-reported measurements as collected daily. Clinical measurements
were performed with the subthreshold stimulation on and the stimulation off (<30 min. on day 5 and 1-week post-stim on day 13), indicated by the black areas. D) Overview of the
self-reported measurements (NRS, PSFS and average duration of spasm) from the baseline to day 13.
S. Soloukey et al. / Brain Stimulation 13 (2020) 637e639638improvement in terms of treatment efﬁcacy, as well as reduction of
side-effects such as loss of muscle force [6].
So far, experimental neuromodulatory research for spasticity
seems to focus mostly on spinal cord stimulation, either epidurally
[7] or transcutaneously [5], but with limited to moderate success
[5,7]. The DRG as a successful target for spasticity has been reported
before in radiofrequency studies [8], in which potential underlying
mechanisms are thought to include long-term depression of synap-
tic transmission and decrease of afferent excitatory input [8]. Inter-
estingly, the use of DRG-neuromodulation rather than DRG-
radiofrequency or other clinically available treatments such as
intrathecal baclofen pumps, introduces unique beneﬁts such as
safe and dynamic patient-tailored targeting of the DRG without se-
vere side-effects such as dizziness, muscle weakness and sedation
[9], warranting further investigation.Our patient also reported a signiﬁcant decrease in chronic lower
back pain during and >7 days post-stimulation. DRG-stimulation,
being in origin a treatment for chronic pain, is known to result in
effective pain relief in the lower back when implanted on L2-L3
DRGs [10]. It would be worthwhile to focus future efforts on pin-
pointing which SCI patient proﬁles might beneﬁt most from DGR-
neuromodulation for pain treatment.
Conclusion
Currently presented results spark interest for further investiga-
tion into the potential beneﬁcial role of DRG-stimulation in spas-
ticity and chronic pain in patients with SCI. However, our case
report also reinstates the difﬁculty of objectively and conclusively
studying treatment strategies for spasticity and pain as such, which
will require special care in future study designs.
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